TACTILE SYSTEMS TECHNOLOGY INC — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Tactile Medical reported Q2 2026 revenue of $85.7M (+9% YoY), gross margin 76% (+100 bps), net income $7.8M (+143% YoY), and adjusted EBITDA $11.4M (+49% YoY). The company inked an exclusive U.S. VA/DoD distribution deal for MyoSleeve wearable compression and launched next-generation AffloVest. However, FY 2026 revenue guidance narrowed to $360–366M from prior $360–368M, citing elevated inventory at DME providers during AffloVest transition. Cash declined to $69.9M from $83.4M (YE 2025) after $5.3M stock buyback and $3.0M paid for exclusive distribution agreement. Full-year adjusted EBITDA guidance held at $49–51M.
Why this rating
Strong operational execution and strategic deals offset modest guidance cut driven by near-term distribution inventory dynamics; core business healthy but near-term uncertainty dampens upside.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.